Matthias Heinzel: It’s in our DNA
Matthias Heinzel, Member of the Executive Board and CEO of Life Science at Merck Group, shared on LinkedIn:
“It’s in our DNA.
Our 27,000 colleagues work every day to support our customers in driving new scientific innovation. I witnessed that this week in Scotland, where we recently expanded our biosafety testing capabilities at our Stirling and Glasgow facilities.
For centuries, Glasgow has been a hub for scientific innovation and that’s still true today. So, it’s no surprise we continue to expand our presence in the area to find new ways to help our customers bring life-changing and life-saving medicines to patients.
It’s in our DNA and it’s our purpose – to impact life and health with science.
These investments continue to enhance our ability to support our customers in developing safe and effective medicines. Biosafety testing is a critical step in the drug development and manufacturing process, ensuring drugs are safe, efficacious, and meet regulatory requirements.
Customers rely on our teams in Scotland, China, Singapore, and the US to ensure drugs are free from contamination and safe for patients.
A big thank you to the team in Scotland for your dedication to our customers and their patients.”
Source: Matthias Heinzel/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023